Intech Biopharm Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Taipei Taiwan (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2012
NCT02165046
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Intech Biopharm | Intech Biopharm Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

budesonide (rhinocort) (6 trials)

Drugs in Phase 2 Trials (2)

albuterol (proventil) (4 trials)

procaterol (3 trials)

Drugs in Phase 1 Trials (3)

fluticasone (cutivate) (2 trials)

formoterol (foradil) (2 trials)

salmeterol (serevent) (2 trials)

Drugs in Other Trials (1)

methacholine (provocholine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Lung Diseases, Obstructive (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 7